ProBioGen’s GlymaxX ADCC enhancement technology, mammalian cell line development and manufacturing services will be employed to advance therapeutic antibodies developed by Inhibrx.
Under the terms of the collaboration, ProBioGen will receive both milestone-dependent license fees, as well as fee-for-service-based payments.
The financial details of the transaction have not been disclosed.